A detailed history of Rhumbline Advisers transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 35,910 shares of FHTX stock, worth $289,793. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,910
Previous 26,739 34.3%
Holding current value
$289,793
Previous $179,000 15.08%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$5.05 - $8.0 $46,313 - $73,368
9,171 Added 34.3%
35,910 $206,000
Q1 2024

May 09, 2024

BUY
$2.82 - $7.94 $2,193 - $6,177
778 Added 3.0%
26,739 $179,000
Q4 2023

Feb 08, 2024

SELL
$2.94 - $6.76 $1,367 - $3,143
-465 Reduced 1.76%
25,961 $167,000
Q3 2023

Nov 09, 2023

BUY
$5.0 - $9.87 $4,995 - $9,860
999 Added 3.93%
26,426 $132,000
Q2 2023

Aug 08, 2023

BUY
$5.37 - $8.84 $606 - $998
113 Added 0.45%
25,427 $179,000
Q1 2023

May 11, 2023

SELL
$4.66 - $8.99 $2,036 - $3,928
-437 Reduced 1.7%
25,314 $157,000
Q4 2022

Feb 14, 2023

BUY
$5.44 - $9.46 $5,293 - $9,204
973 Added 3.93%
25,751 $164,000
Q3 2022

Nov 10, 2022

BUY
$7.52 - $18.01 $12,791 - $30,635
1,701 Added 7.37%
24,778 $213,000
Q2 2022

Aug 11, 2022

BUY
$8.48 - $16.84 $3,400 - $6,752
401 Added 1.77%
23,077 $314,000
Q1 2022

May 12, 2022

BUY
$8.87 - $22.1 $28,588 - $71,228
3,223 Added 16.57%
22,676 $345,000
Q4 2021

Feb 10, 2022

BUY
$10.79 - $22.87 $10,563 - $22,389
979 Added 5.3%
19,453 $445,000
Q3 2021

Nov 12, 2021

BUY
$8.33 - $15.02 $23,448 - $42,281
2,815 Added 17.98%
18,474 $257,000
Q2 2021

Aug 05, 2021

BUY
$9.32 - $13.26 $145,941 - $207,638
15,659 New
15,659 $167,000

Others Institutions Holding FHTX

About Foghorn Therapeutics Inc.


  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $336M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.